196 related articles for article (PubMed ID: 37787493)
1. Veliparib (ABT-888), a PARP inhibitor potentiates the cytotoxic activity of 5-fluorouracil by inhibiting MMR pathway through deregulation of MSH6 in colorectal cancer stem cells.
Paul S; Chatterjee S; Sinha S; Dash SR; Pradhan R; Das B; Goutam K; Kundu CN
Expert Opin Ther Targets; 2023; 27(10):999-1015. PubMed ID: 37787493
[TBL] [Abstract][Full Text] [Related]
2. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
de Castro E Gloria H; Jesuíno Nogueira L; Bencke Grudzinski P; da Costa Ghignatti PV; Guecheva TN; Motta Leguisamo N; Saffi J
BMC Cancer; 2021 Apr; 21(1):448. PubMed ID: 33888065
[TBL] [Abstract][Full Text] [Related]
3. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
Oliver JA; Ortiz R; Jimenez-Luna C; Cabeza L; Perazzoli G; Caba O; Mesas C; Melguizo C; Prados J
J Biosci; 2020; 45():. PubMed ID: 33097678
[TBL] [Abstract][Full Text] [Related]
4. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
[TBL] [Abstract][Full Text] [Related]
5. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
[TBL] [Abstract][Full Text] [Related]
6. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
Adamsen BL; Kravik KL; De Angelis PM
Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
[TBL] [Abstract][Full Text] [Related]
7. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures.
Shakibaei M; Buhrmann C; Kraehe P; Shayan P; Lueders C; Goel A
PLoS One; 2014; 9(1):e85397. PubMed ID: 24404205
[TBL] [Abstract][Full Text] [Related]
8. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Geng L; Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
PLoS One; 2011; 6(12):e28862. PubMed ID: 22194930
[TBL] [Abstract][Full Text] [Related]
10. ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
Siddharth S; Nayak D; Nayak A; Das S; Kundu CN
DNA Repair (Amst); 2016 Sep; 45():44-55. PubMed ID: 27334689
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Huehls AM; Wagner JM; Huntoon CJ; Geng L; Erlichman C; Patel AG; Kaufmann SH; Karnitz LM
Cancer Res; 2011 Jul; 71(14):4944-54. PubMed ID: 21613406
[TBL] [Abstract][Full Text] [Related]
12. ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
Narayan S; Ramisetti S; Jaiswal AS; Law BK; Singh-Pillay A; Singh P; Amin S; Sharma AK
Eur J Med Chem; 2019 Jan; 161():456-467. PubMed ID: 30384048
[TBL] [Abstract][Full Text] [Related]
13. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
Arnold CN; Goel A; Boland CR
Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
[TBL] [Abstract][Full Text] [Related]
14. Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6.
Tomicic MT; Steigerwald C; Rasenberger B; Brozovic A; Christmann M
Arch Toxicol; 2019 Aug; 93(8):2265-2277. PubMed ID: 31289894
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44 is regulated by ELF3 in 5-FU treated colorectal cancer cells.
Li F; Qiu F; Fan X; Yu Q; Liu S; Guo Y; Zhu Y; Xi X; Du B
Gene; 2024 Jan; 892():147896. PubMed ID: 37832805
[TBL] [Abstract][Full Text] [Related]
16. Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
Kong L; Wang X; Zhang K; Yuan W; Yang Q; Fan J; Wang P; Liu Q
PLoS One; 2015; 10(9):e0137888. PubMed ID: 26368019
[TBL] [Abstract][Full Text] [Related]
17. 7
Su Y; Choi HS; Choi JH; Kim HS; Jang YS; Seo JW
Mar Drugs; 2023 Jan; 21(2):. PubMed ID: 36827121
[TBL] [Abstract][Full Text] [Related]
18. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
[TBL] [Abstract][Full Text] [Related]
19. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.
Buhrmann C; Yazdi M; Popper B; Shayan P; Goel A; Aggarwal BB; Shakibaei M
Nutrients; 2018 Jul; 10(7):. PubMed ID: 30002278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
